The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -12.07 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.96 — no flag raisedOK
- Earnings quality 76/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Lineage Cell Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Collaboration Revenues$13.6M
- Event Based Milestones And Other Collaborative Revenue$7.2M
- Upfront License Fees$6.4M
- Royalties License And Other Revenues$947K
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-12
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Lineage Cell Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Lineage Cell Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.